Picture of Scancell Holdings logo

SCLP Scancell Holdings Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+17.92%
3m+99.65%
6m+84.85%
1yr+10.21%
Volume Change (%)
10d/3m+88.24%
Price vs... (%)
52w High-8.24%
50d MA+39.94%
200d MA+68.64%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-17%
Return on Equity-10.99%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Apr 202330th Apr 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Scancell Holdings EPS forecast chart

Profile Summary

Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies for the treatment of cancer and infectious disease. Its technology includes ImmunoBody, GlyMab, Moditope, and AvidiMab. Its products pipeline include SCIB1 & iSCIB1+, SCIB2 & iSCIB2, Modi-1, Modi-2, and SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Its SCIB1, is developed for the treatment of patients with metastatic melanoma. SCIB1 consists of SCIB1-001 and SCIB1-002. Its SCIB2 is the second cancer vaccine based on the ImmunoBody technology. The SCIB2 & iSCIB2 vaccine is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. Modi-1 is based on Moditope platform, which is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. Modi-2 targets homocitrullinated cancer antigens, to address different cancer indications to Modi-1, including tumors.

Directors

Last Annual
April 30th, 2022
Last Interim
April 30th, 2022
Incorporated
April 14th, 2008
Public Since
July 30th, 2010
No. of Employees
40
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
815,218,831

SCLP Share Price Performance

Upcoming Events for SCLP

Half Year 2023 Scancell Holdings PLC Earnings Release

Similar to SCLP

Picture of 4Basebio logo

4Basebio

gb flag iconLondon Stock Exchange

Picture of 4d Pharma logo

4d Pharma

gb flag iconLondon Stock Exchange

Picture of Allergy Therapeutics logo

Allergy Therapeutics

gb flag iconLondon Stock Exchange

Picture of Arecor Therapeutics logo

Arecor Therapeutics

gb flag iconLondon Stock Exchange

Picture of Avacta logo

Avacta

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email